Featured Research

from universities, journals, and other organizations

Photodynamic Therapy Shows Promise In Halting Progression Of Age-Related Macular Degeneration

Date:
April 19, 2000
Source:
Emory University Health Sciences Center
Summary:
Photodynamic therapy (PDT), a treatment for age-related macular degeneration under study at Emory University and other sites, has received Food and Drug Administration (FDA) approval. Emory Eye Center can now offer new hope to patients with the wet form of age-related macular degeneration (AMD), the leading cause of blindness in Americans over age 50.

April 13, 2000 -- Photodynamic therapy (PDT), a treatment for age-related macular degeneration under study at Emory University and other sites, received Food and Drug Administration (FDA) approval today.

Related Articles


Emory Eye Center can now offer new hope to patients with the wet form of age-related macular degeneration (AMD), the leading cause of blindness in Americans over age 50.

PDT is significant because there is no cure for wet AMD and the most widely available treatment -- photocoagulation therapy with a heating laser -- can cause blind spots and can be used for about 10 percent of patients with the disease. About 40 to 60% of the estimated 200,000 patients who are diagnosed each year with wet AMD may be eligible for PDT.

According to Paul Sternberg Jr., M.D., director of the retina section at the Emory Eye Center, "PDT uses a combination of low-level laser light with a drug to stop the macula-destroying effects of the disorder. PDT is a promising alternative to the growing number of treatments we now can offer macular degeneration patients. The therapy appears to be is safer with fewer risks than photocoagulation therapy."

AMD affects more than one-fourth of all Americans over age 75. No one knows what causes the disorder or how to prevent it. AMD affects central part of the retina or the macula, the area of sharpest sight and the part we use for reading and central vision.

The wet or exudative form of AMD -- the most blinding form -- results when abnormal blood vessels form and leak fluid and blood underneath the retina in the layer of the retina in the back of the eye called the choroid. The choroid's blood vessels, combined with tissue, can form a scar-like membrane under the retina and block central vision.

The goal of PDT is to seal leaking blood vessels and slow or stop the progression of vision loss. During PDT, the patient receives an injection of a photosensitizer drug that concentrates in the abnormal blood vessels from the choroid. A non-thermal laser light shone onto the retina activates the drug. The therapy is outpatient and patients can return to normal activities immediately, though they will need to stay out of direct sunlight for at least 24 hours. Most need repeat treatments later to enhance results.

Following treatments, patients sometimes will experience a temporary reduction of vision, which will improve over the next few weeks. Research shows that the therapy preserves or improves vision (defined as no loss of visual acuity or a deterioration of less than four acuity lines on an eye chart) in 38% of patients and slows vision loss in another 31 percent.

The Emory Eye Center was one of about 30 centers worldwide that participated in Phase III clinical trials carried out by CIBA Vision of Atlanta (QLT PhotoTherapeutics of Vancouver, Canada, makes the dye and Carl Zeiss makes the laser). The therapy is marketed as Visudyne™ therapy.


Story Source:

The above story is based on materials provided by Emory University Health Sciences Center. Note: Materials may be edited for content and length.


Cite This Page:

Emory University Health Sciences Center. "Photodynamic Therapy Shows Promise In Halting Progression Of Age-Related Macular Degeneration." ScienceDaily. ScienceDaily, 19 April 2000. <www.sciencedaily.com/releases/2000/04/000417100606.htm>.
Emory University Health Sciences Center. (2000, April 19). Photodynamic Therapy Shows Promise In Halting Progression Of Age-Related Macular Degeneration. ScienceDaily. Retrieved November 24, 2014 from www.sciencedaily.com/releases/2000/04/000417100606.htm
Emory University Health Sciences Center. "Photodynamic Therapy Shows Promise In Halting Progression Of Age-Related Macular Degeneration." ScienceDaily. www.sciencedaily.com/releases/2000/04/000417100606.htm (accessed November 24, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Monday, November 24, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Are Female Bosses More Likely To Be Depressed?

Are Female Bosses More Likely To Be Depressed?

Newsy (Nov. 24, 2014) A new study links greater authority with increased depressive symptoms among women in the workplace. Video provided by Newsy
Powered by NewsLook.com
Winter Can Cause Depression — Here's How To Combat It

Winter Can Cause Depression — Here's How To Combat It

Newsy (Nov. 23, 2014) Millions of American suffer from seasonal depression every year. It can lead to adverse health effects, but there are ways to ease symptoms. Video provided by Newsy
Powered by NewsLook.com
Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

Ebola-Hit Sierra Leone's Late Cocoa Leaves Bitter Taste

AFP (Nov. 23, 2014) The arable district of Kenema in Sierra Leone -- at the centre of the Ebola outbreak in May -- has been under quarantine for three months as the cocoa harvest comes in. Duration: 01:32 Video provided by AFP
Powered by NewsLook.com
Don't Fall For Flu Shot Myths

Don't Fall For Flu Shot Myths

Newsy (Nov. 23, 2014) Misconceptions abound when it comes to your annual flu shot. Medical experts say most people older than 6 months should get the shot. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins